Tempus and Medtronic Announce ALERT Trial Results

AI-Driven EHR Notifications Improve Treatment for Significant Medical Conditions

Apr. 1, 2026 at 2:13pm

Got story updates? Submit your updates here. ›

Tempus, a leading provider of artificial intelligence and precision medicine solutions, and Medtronic, a global leader in healthcare technology, have announced the results of the ALERT clinical trial. The trial demonstrated that AI-driven electronic health record (EHR) notifications can significantly improve treatment outcomes for patients with serious medical conditions.

Why it matters

The ALERT trial results highlight the potential of AI-powered EHR systems to enhance clinical decision-making and patient care. By providing real-time alerts and recommendations to healthcare providers, these technologies can help ensure timely and appropriate treatment, leading to better outcomes for patients.

The details

The ALERT trial was a large-scale, randomized controlled study that evaluated the impact of AI-driven EHR notifications on the management of patients with conditions such as heart failure, sepsis, and acute kidney injury. The trial involved over 10,000 patients across multiple healthcare systems and found that the use of the AI-powered system resulted in significant improvements in treatment adherence, reduced hospital readmissions, and lower mortality rates compared to standard care.

  • The ALERT trial was conducted over a 2-year period, from 2024 to 2026.
  • The trial results were announced on April 1, 2026.

The players

Tempus

A leading provider of artificial intelligence and precision medicine solutions.

Medtronic

A global leader in healthcare technology.

Got photos? Submit your photos here. ›

What they’re saying

“The ALERT trial results demonstrate the transformative potential of AI-driven EHR systems to improve patient outcomes and enhance the delivery of care.”

— Eric Lefkofsky, CEO, Tempus

“We are excited to partner with Tempus to bring this innovative technology to healthcare providers and patients, helping to ensure timely and appropriate treatment for critical medical conditions.”

— Geoff Martha, Chairman and CEO, Medtronic

What’s next

Tempus and Medtronic plan to expand the ALERT system to additional healthcare systems and medical conditions, with the goal of improving patient outcomes and reducing healthcare costs.

The takeaway

The ALERT trial results demonstrate the significant potential of AI-powered EHR systems to transform healthcare delivery and improve patient outcomes. By providing real-time alerts and recommendations to clinicians, these technologies can help ensure that patients receive the right treatment at the right time, leading to better health outcomes and reduced healthcare costs.